Elysium announced the launch of The Elysium Longevity Institute (TELI), a science-first, physician-led longevity program that expands the company’s offerings to include personalized supplement and prescription protocols, peptides, vitamin injections and ongoing clinical support.
TELI will be led by chief medical officer Omar Baker, M.D., who most recently served as executive vice president and deputy chief medical officer at UnitedHealth Group, and will collaborate with Elysium co-founder and chief scientist Leonard Guarente, Ph.D., Novartis Professor of Biology at MIT.
The company claims TELI builds on more than a decade of translational research and participation in over 20 clinical trials.
At launch, the program will provide therapies across four areas: healthy aging; energy, performance and recovery; detox and inflammation; and metabolic health. Initial patient enrollment is limited to 10,000 with a waitlist open, and TELI is expected to begin enrollment in Q3 2026, according to the company.
